547 related articles for article (PubMed ID: 10595257)
1. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
[TBL] [Abstract][Full Text] [Related]
2. Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer.
Dørum A; Heimdal K; Hovig E; Inganäs M; Møller P
Am J Hum Genet; 1999 Sep; 65(3):671-9. PubMed ID: 10441573
[TBL] [Abstract][Full Text] [Related]
3. Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.
Dørum A; Hovig E; Tropé C; Inganas M; Møller P
Eur J Cancer; 1999 May; 35(5):779-81. PubMed ID: 10505039
[TBL] [Abstract][Full Text] [Related]
4. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
Heimdal K; Maehle L; Apold J; Pedersen JC; Møller P
Eur J Cancer; 2003 Oct; 39(15):2205-13. PubMed ID: 14522380
[TBL] [Abstract][Full Text] [Related]
5. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Meindl A;
Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
[TBL] [Abstract][Full Text] [Related]
7. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.
Kringen P; Wang Y; Dumeaux V; Nesland JM; Kristensen G; Borresen-Dale AL; Dorum A
BMC Cancer; 2005 Oct; 5():134. PubMed ID: 16229746
[TBL] [Abstract][Full Text] [Related]
9. Costs and benefits of diagnosing familial breast cancer.
Heimdal K; Maehle L; Møller P
Dis Markers; 1999 Oct; 15(1-3):167-73. PubMed ID: 10595273
[TBL] [Abstract][Full Text] [Related]
10. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
Kumar BV; Lakhotia S; Ankathil R; Madhavan J; Jayaprakash PG; Nair MK; Somasundaram K
Cancer Biol Ther; 2002; 1(1):18-21. PubMed ID: 12170759
[TBL] [Abstract][Full Text] [Related]
11. Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.
Plakhins G; Irmejs A; Gardovskis A; Subatniece S; Rozite S; Bitina M; Keire G; Purkalne G; Teibe U; Trofimovics G; Miklasevics E; Gardovskis J
BMC Med Genet; 2011 Oct; 12():147. PubMed ID: 22032251
[TBL] [Abstract][Full Text] [Related]
12. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
[TBL] [Abstract][Full Text] [Related]
13. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
[TBL] [Abstract][Full Text] [Related]
14. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
Claes K; Machackova E; De Vos M; Poppe B; De Paepe A; Messiaen L
Dis Markers; 1999 Oct; 15(1-3):69-73. PubMed ID: 10595255
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
Einbeigi Z; Bergman A; Meis-Kindblom JM; Flodin A; Bjursell C; Martinsson T; Kindblom LG; Wahlström J; Wallgren A; Nordling M; Karlsson P
Fam Cancer; 2007; 6(1):35-41. PubMed ID: 16944270
[TBL] [Abstract][Full Text] [Related]
16. Genetic epidemiology of BRCA1 mutations in Norway.
Møller P; Heimdal K; Apold J; Fredriksen A; Borg A; Hovig E; Hagen A; Hagen B; Pedersen JC; Maehle L; ;
Eur J Cancer; 2001 Dec; 37(18):2428-34. PubMed ID: 11720839
[TBL] [Abstract][Full Text] [Related]
17. The contribution of founder mutations in BRCA1 to breast cancer in Belarus.
Uglanitsa N; Oszurek O; Uglanitsa K; Savonievich E; Lubiński J; Cybulski C; Debniak T; Narod SA; Gronwald J
Clin Genet; 2010 Oct; 78(4):377-80. PubMed ID: 20507347
[TBL] [Abstract][Full Text] [Related]
18. Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
Chang-Claude J; Dong J; Schmidt S; Shayeghi M; Komitowski D; Becher H; Stratton MR; Royer-Pokora B
J Med Genet; 1998 Feb; 35(2):116-21. PubMed ID: 9507390
[TBL] [Abstract][Full Text] [Related]
19. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
